STOCK TITAN

Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Exagen (Nasdaq: XGN) will announce financial results for Q2 2022 on August 4, 2022, post-market. A conference call led by CEO Ron Rocca and CFO Kamal Adawi is scheduled for 4:30 PM ET. Participants can join via phone or webcast through Exagen's investor relations website. A replay of the call will be accessible until August 18, 2022. Exagen specializes in autoimmune diagnostics and is focused on enhancing precision medicine through its AVISE® testing and ongoing product pipeline development.

Positive
  • Focus on precision medicine and investment in product pipeline.
Negative
  • None.

SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2022, after the market close on Thursday, August 4, 2022. Ron Rocca, Exagen’s President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company’s results at 4:30 PM ET (1:30 PM PT).

Interested parties may access the conference call by dialing (404) 267-0369 (U.S.) or (888) 437-3179 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com.

A replay of the conference call will be available until Thursday, August 18, 2022, at 11:59 PM ET (8:59 PM PT). Interested parties may access the replay of the conference call by dialing (201) 612-7415 (U.S.) or (877) 660-6853 (international) using passcode 13731768. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes.

About Exagen Inc.

Exagen (Nasdaq: XGN) is a leading provider of autoimmune diagnostic, prognostic, and monitoring testing solutions. Exagen is a patient focused, discovery driven organization built on the success of AVISE® testing and is investing in its product pipeline to support patients throughout their autoimmune diagnosis and treatment journeys. The goal at Exagen is to assist patients, physicians, and payors by enabling precision medicine. Exagen is located in San Diego County with clinical and research and development laboratories in Vista, CA.

For more information, please visit Exagen.com and follow @ExagenInc on Twitter.

CONTACTS:

Investor Relations
Exagen Inc.
Ryan Douglas
rdouglas@exagen.com
760.560.1525

Company
Exagen Inc.
Kamal Adawi, Chief Financial Officer
kadawi@exagen.com
760.477.5514


FAQ

When will Exagen release its financial results for Q2 2022?

Exagen will release its financial results on August 4, 2022.

What time is Exagen's conference call for Q2 2022 results?

The conference call is scheduled for 4:30 PM ET on August 4, 2022.

How can I access Exagen's Q2 2022 conference call?

You can access the conference call by dialing (404) 267-0369 or (888) 437-3179, or via webcast on Exagen's investor relations website.

What is Exagen's focus as a company?

Exagen focuses on providing autoimmune diagnostic, prognostic, and monitoring testing solutions.

How long will the replay of Exagen's Q2 2022 conference call be available?

The replay will be available until August 18, 2022.

Exagen Inc.

NASDAQ:XGN

XGN Rankings

XGN Latest News

XGN Stock Data

71.34M
9.30M
29.74%
57.22%
0.3%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
VISTA